Art. -Nr.: HY-152226

MC2590

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

MC2590 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2590 is a inhibitor of HDAC1-3, -6, -8, and -10 (class I/IIb-selective inhibitor) with IC₅₀s of 0.015 μM-0.156 μM. MC2590 also inhibits HDAC isoforms HDAC4, HDAC5, HDAC7, HDAC9, HDAC11 with IC₅₀s of 1.35 μM-3.98 μM. MC2625 induces G2/M cell cycle arrest and modulates pro- and anti-apoptotic microRNAs towards apoptosis induction.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.71%
CAS. Nr.: 2284460-01-9
Formel: C₂₀H₁₇N₃O₃
Molecular Weight:347.37

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

MC2590 Chemical Structure

CAS. Nr.: 2284460-01-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

HDAC1

0.098 μM (IC₅₀)

HDAC2

0.156 μM (IC₅₀)

HDAC3

0.039 μM (IC₅₀)

HDAC6

0.015 μM (IC₅₀)

HDAC8

0.047 μM (IC₅₀)

HDAC10

0.071 μM (IC₅₀)

HDAC4

2.73 μM (IC₅₀)

HDAC5

1.35 μM (IC₅₀)

HDAC7

2.06 μM (IC₅₀)

HDAC9

2.79 μM (IC₅₀)

HDAC11

3.98 μM (IC₅₀)

Alle HDAC Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.32 μM Compound: 5e; MC2590	Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
HCT-116	IC₅₀	0.07 μM Compound: 5e; MC2590	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
HFF	IC₅₀	>10000 nM Compound: 6	Cytotoxicity against HFF Cytotoxicity against HFF	[PMID: 30366254]
HL-60	IC₅₀	0.276 μM Compound: 5e; MC2590	Antiproliferative activity against human HL-60 cells incubated for 48 hrs Antiproliferative activity against human HL-60 cells incubated for 48 hrs	[PMID: 36549114]
K562	IC₅₀	0.05 μM Compound: 5e; MC2590	Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
KARPAS-299	IC₅₀	0.4 μM Compound: 5e; MC2590	Antiproliferative activity against human KARPAS-299 cells incubated for 48 hrs Antiproliferative activity against human KARPAS-299 cells incubated for 48 hrs	[PMID: 36549114]
Kasumi 1	IC₅₀	0.066 μM Compound: 5e; MC2590	Antiproliferative activity against human Kasumi 1 cells incubated for 48 hrs Antiproliferative activity against human Kasumi 1 cells incubated for 48 hrs	[PMID: 36549114]
MV4-11	IC₅₀	0.059 μM Compound: 5e; MC2590	Antiproliferative activity against human MV4-11 cells incubated for 48 hrs Antiproliferative activity against human MV4-11 cells incubated for 48 hrs	[PMID: 36549114]
NB-4	IC₅₀	0.084 μM Compound: 5e; MC2590	Antiproliferative activity against human NB4 cells incubated for 48 hrs Antiproliferative activity against human NB4 cells incubated for 48 hrs	[PMID: 36549114]
OCI-AML2	IC₅₀	0.379 μM Compound: 5e; MC2590	Antiproliferative activity against human OCI-AML2 cells incubated for 48 hrs Antiproliferative activity against human OCI-AML2 cells incubated for 48 hrs	[PMID: 36549114]
OCI-AML-3	IC₅₀	0.529 μM Compound: 5e; MC2590	Antiproliferative activity against human OCI-AML-3 cells incubated for 48 hrs Antiproliferative activity against human OCI-AML-3 cells incubated for 48 hrs	[PMID: 36549114]
U-937	IC₅₀	0.258 μM Compound: 5e; MC2590	Antiproliferative activity against human U-937 cells incubated for 48 hrs Antiproliferative activity against human U-937 cells incubated for 48 hrs	[PMID: 36549114]

In Vitro

MC2625 (compound 5e) has antiproliferative activity with Colorectal carcinoma HCT116 (IC₅₀=0.07 μM), Lung adenocarcinoma A549 (IC₅₀=0.32 μM), Chronic myelogenous leukaemia K562 (IC₅₀=0.05 μM) for 72 h^[1].
MC2625 (1, 5 μM; 24, 48 h) displays mainly G2/M cell cycle arrest^[1].
MC2625 (1, 5 μM; 24, 48 h) reveals H3K9/14 hyperacetylation activity, increases the acetyl-α-tubulin level, markedly upregulates the p21 protein^[1].
MC2625 (1, 5 μM; 48 h) increases mRNA expression of p21, BAX and BAK, downregulates cyclin D1 and BCL-2 and modulates pro- and anti-apoptotic microRNAs towards apoptosis induction^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

Human acute myeloid leukaemia U937 cells
Concentration:

1, 5 μM
Incubation Time:

24, 48 h
Result:

At 24 h, showed very low increase of the pre-G1 peak and led to a G2/M phase arrest at 1 μM; induced a 10% pre-G1 increase and displayed a block at the G2/M phase at 5 μM.
At 48 h, induced a 70-85% block of the cell cycle at the G1 phase.

Western Blot Analysis^[1]

Cell Line:

Human acute myeloid leukaemia U937 cells
Concentration:

1, 5 μM
Incubation Time:

24, 48 h
Result:

At 1 μM revealed H3K9/14 hyperacetylation activity, increased the acetyl-α-tubulin level, markedly upregulated the p21 protein.

RT-PCR^[1]

Cell Line:

Human acute myeloid leukaemia U937 cells
Concentration:

1, 5 μM
Incubation Time:

48 h
Result:

At 1 μM significantly induced the expression of BAX and BAK, dose-dependently downregulated the antiapoptotic factor BCL-2.
Downregulated miRNAs with antiapoptotic activity (miR-17-5p, miR-18-5p, miR-19b-3p, miR-20a-5p, miR-21-5p); induced the proapoptotic miRNAs (miR-let7a-5p, miR-125b-5p, miR-181a-5p, miR-181b-5p, miR-769-5p, miR-122-5p).

Chemical Information

CAS. Nr. 2284460-01-9
Appearance Solid
Molecular Weight 347.37
Formel C₂₀H₁₇N₃O₃
Color Off-white to light yellow
SMILES

O=C(NO)/C=C/C1=NC=C(C=C1)NC(CC2=C3C=CC=CC3=CC=C2)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Int J Parasitol Drugs Drug Resist

2026 May 17;31:100649.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (287.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8788 mL

14.3939 mL

28.7877 mL

5 mM

0.5758 mL

2.8788 mL

5.7575 mL

10 mM

0.2879 mL

1.4394 mL

2.8788 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Elisabetta Di Bello, et al. Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells. Eur J Med Chem. 2022 Dec 15;247:115022. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8788 mL	14.3939 mL	28.7877 mL	71.9694 mL
	5 mM	0.5758 mL	2.8788 mL	5.7575 mL	14.3939 mL
	10 mM	0.2879 mL	1.4394 mL	2.8788 mL	7.1969 mL
	15 mM	0.1919 mL	0.9596 mL	1.9192 mL	4.7980 mL
	20 mM	0.1439 mL	0.7197 mL	1.4394 mL	3.5985 mL
	25 mM	0.1152 mL	0.5758 mL	1.1515 mL	2.8788 mL
	30 mM	0.0960 mL	0.4798 mL	0.9596 mL	2.3990 mL
	40 mM	0.0720 mL	0.3598 mL	0.7197 mL	1.7992 mL
	50 mM	0.0576 mL	0.2879 mL	0.5758 mL	1.4394 mL
	60 mM	0.0480 mL	0.2399 mL	0.4798 mL	1.1995 mL
	80 mM	0.0360 mL	0.1799 mL	0.3598 mL	0.8996 mL
	100 mM	0.0288 mL	0.1439 mL	0.2879 mL	0.7197 mL

MC2590

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MC2590

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MC2590

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MC2590

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MC2590

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MC2590 Related Classifications

HY-152226 Related Classifications